Item distribution and missing data
| Item | Floor (%) | Ceiling (%) | Missing (%) |
| Patient-reported outcome | |||
| Q.8 Problem related to health* | 59.1 | 32.3 | 8.6 |
| Q.9 Mobility aids or assistive devices | 0.1 | 0 | 11.5 |
| Q.10 Pain medications | 3.0 | 14.6 | 12.3 |
| Q.11.1 Acute pain (activities) | 0.7 | 33.1 | 12.8 |
| Q.11.2 Acute pain (interference) | 0.3 | 33.2 | 12.8 |
| Q.12.1 Chronic pain (activities) | 1.4 | 32.6 | 13.5 |
| Q.12.2 Chronic pain (interference) | 0.1 | 33.6 | 13.5 |
| Q.13 Daily activities | 0.1 | 42.4 | 14.3 |
| Q.14 Work/school life | 0.1 | 27.8 | 21.8 |
| Q.15 Joint surgery or procedure | 1.3 | 52.4 | 17.0 |
| Q.16 Comorbid diseases | 0 | 56.1 | 0 |
| Haemophilia-related health | |||
| Q.17 Severity | N/A | N/A | 17.3 |
| Q.18 Inhibitor status | N/A | N/A | 19.1 |
| Q.19 Bleeding in the past 12 months | 16.6 | 8.5 | 18.2 |
| Q.20 Bleeding in the past 2 weeks | N/A | N/A | 18.9 |
| Q.21 Haemophilia treatment centre | N/A | N/A | 19.4 |
| Q.25 Target joints | N/A | N/A | 22.6 |
| Q. 26 Spontaneous joint bleeding | N/A | N/A | 49.4 |
| Q.27 Limitation of range of motion* | 66.6 | 11.4 | 22.0 |
| Q.28 Life-threatening or limb-threatening bleeding* | 15.2 | 62.1 | 22.8 |
| EQ-5D-5L and EQ-VAS | |||
| Mobility | 1.1 | 32.4 | 21.6 |
| Self-care | 0.7 | 55.0 | 22.3 |
| Usual activities | 0.7 | 37.9 | 22.4 |
| Pain/discomfort | 1.1 | 23.9 | 22.9 |
| Anxiety/depression | 1.6 | 37.3 | 22.8 |
| VAS | 0 | 3.1 | 22.8 |
*Dichotomous outcome.
EQ-5D-5L, EuroQol five dimension 5-level instrument; EQ-VAS, EuroQol visual analogue scale; N/A, not applicable.